Article in Lab on a chip, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Solomon OshabaheebwaDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0001-8949-7524
Utku GorekeInnovative Genomics Institute, University of California, Berkeley, CA, USA.ORCID 0000-0001-7973-9120
Yuxuan DuDepartment of Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA. umut@case.edu.
Christopher L WirthDepartment of Chemical and Biomolecular Engineering, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0003-3380-2029
Zoe SekyondaDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.
Bryan L BensonDepartment of Anesthesiology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.ORCID 0000-0003-4318-5693
Payam FadaeiDepartment of Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA. umut@case.edu.
Yusang B LeyDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.
Nathan M PerezInnovative Genomics Institute, University of California, Berkeley, CA, USA.
Petros GiannikopoulosInnovative Genomics Institute, University of California, Berkeley, CA, USA.
David N NguyenInnovative Genomics Institute, University of California, Berkeley, CA, USA.ORCID 0000-0001-6808-2717
Michael A SusterDepartment of Electrical, Computer, and Systems Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA. pxm89@case.edu.
Pedram MohseniDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0002-2849-4677
Umut A GurkanDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0002-0331-9960
Funding
Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages to Equity in Health (CLE Health)UM1TR004528 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI GRACE A MCCOMSEY · 2023 to 2026
$32.1M
HLS-Affordable, quantitative microchip-electrophoresis for sickle cell disease screeningR44HL140739 · NHLBI · HEMEX HEALTH, INC. · PI GALEN, PETER · 2018 to 2025
$4.7M
Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability (Administrative Supplement)R42HL162214 · NHLBI · BIOCHIP LABS, INC. · PI FEDERICI, CHIARA, GURKAN, UMUT A. · 2022 to 2024
$2.1M
Portable, affordable, quantitative microchip electrophoresis for hemoglobin A1C testingR42DK119048 · NIDDK · HEMEX HEALTH, INC. · PI GALEN, PETER · 2022 to 2023
$1.7M
A Modality-Agnostic Potency Assay Enabling Both Ex Vivo and In Vivo Genome Editing Therapeutics for Sickle Cell DiseaseU01AI176469 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI GIANNIKOPOULOS, PETROS, GURKAN, UMUT A. · 2023 to 2025
$1.4M
Strengthening Research Capacity in Innovative Global Health Technologies for Non-Communicable Diseases in UgandaD43TW012260 · FIC · CASE WESTERN RESERVE UNIVERSITY · PI ANDREW Martin ROLLINS, Robert Ssekitoleko · 2022 to 2026
$1.2M
Microfluidic Impedance Red Cell Assay (MIRCA) for Emerging Pharmacologic and Gene based Therapies for Sickle Cell DiseaseR56HL165946 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI GURKAN, UMUT A. · 2022 to 2022
$663k
RHODA: Rapid Hemoglobin-Oxygen Dissociation AssayR41HL172662 · NHLBI · HEMEX HEALTH, INC. · PI GALEN, PETER, GURKAN, UMUT A. · 2024 to 2024
Emerging therapies in sickle cell disease (SCD) aim to restore healthy red blood cell (RBC) function, but they often yield heterogeneous cellular responses. There are no proven techniques to evaluate restored rheological functionality and heterogeneity in these RBCs. We present a biomimetic microcapillary network, high-speed imaging, and computational algorithms to analyze RBC capillary velocity profiles of the entire sample population at single-cell resolution. Using peripheral RBCs from SCD patients and healthy donors, we showed that RBC capillary transit velocity correlated with cell shape, hydrodynamic adaptability, and elongation index. Healthy RBCs exhibited a velocity distribution skewed toward higher values, whereas RBCs from individuals with SCD showed a shift toward lower velocities. SCD samples had a greater fraction of slow RBCs than healthy controls (42.1% ± 12.0%
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.